Introduction
For decades, Alzheimer’s disease treatment focused only on managing symptoms like memory loss and confusion. Those older drugs did not change the disease itself. Today, that is changing. The FDA has approved two new medications that target the underlying biology of Alzheimer’s. These drugs are designed to slow cognitive decline in people with early-stage disease. If you or a loved one are exploring treatment options, understanding how these medications work, what they cost, and how to get insurance coverage is the first step.
How the New FDA-Approved Drugs Work
Alzheimer’s disease is linked to the buildup of abnormal proteins in the brain. Two main proteins cause trouble: amyloid plaques and tau tangles. The new FDA-approved medications are monoclonal antibodies. These are lab-made proteins that travel through the bloodstream to the brain. They attach to amyloid plaques and help the immune system clear them out. Removing these plaques does not cure Alzheimer’s, but clinical trials show it can slow the progression of symptoms by about 25 to 35 percent over 18 months.
These medications are only approved for people with mild cognitive impairment (MCI) or mild dementia caused by Alzheimer’s. They are not for moderate or severe stages. Before starting, doctors must confirm the presence of amyloid using a PET scan or a spinal fluid test. Treatment requires regular MRI scans to monitor for a rare side effect called brain swelling or microbleeds, known medically as ARIA.
Lecanemab (Brand Name: Leqembi)
Lecanemab received full FDA approval in July 2023. It is given as an intravenous infusion every two weeks. Patients typically take the drug for at least 18 months. The medication requires monthly MRI scans during the first six months, then every three months after that. Clinical data shows the greatest benefit comes when treatment starts early in the disease course.
Donanemab (Brand Name: Kisunla)
Donanemab received full FDA approval in July 2024. It is given as an intravenous infusion every four weeks. A unique feature of this drug is that treatment can stop once follow-up PET scans show that amyloid plaques have been cleared from the brain. Like lecanemab, it requires regular MRI monitoring for ARIA. Both drugs carry a boxed warning for brain swelling and bleeding, which is why careful screening and monitoring are required.
Real Costs: What to Expect Out of Pocket
The list price for these medications is high, but the total cost includes more than just the drug itself. Understanding the full financial picture helps you plan ahead and avoid surprise bills.
- Medication Cost: Both lecanemab and donanemab cost roughly $26,500 to $27,000 per year.
- Infusion Fees: Each clinic visit costs between $500 and $1,500. This covers the nurse time, IV supplies, and monitoring during the 60 to 90 minute infusion.
- MRI Monitoring: Brain MRIs are required every 4 to 6 months. Without insurance, each scan costs $1,000 to $2,500 depending on the facility.
- Total Annual Cost: Before insurance, the combined cost of the drug, infusions, and MRIs typically falls between $40,000 and $50,000 per year.
These prices are based on current manufacturer list prices. Actual costs vary by state, clinic type, and insurance plan. Many patients use manufacturer support programs to lower their out-of-pocket expenses.
What Medicare and Private Insurance Cover
Insurance coverage for Alzheimer’s disease-modifying drugs has improved significantly over the last two years. Knowing how your plan works will save you time and money.
Medicare Coverage
In December 2023, the Centers for Medicare & Medicaid Services (CMS) announced broad coverage for amyloid-modifying drugs. Medicare Part B covers the infusion and the MRI monitoring scans. You will pay your annual Part B deductible first, then 20 percent coinsurance for the drug and clinic fees. Many patients use Medigap supplemental plans or Medicare Advantage plans to cover that 20 percent gap. You must be enrolled in Part B to receive these treatments.
Private Insurance Coverage
Most major private insurers now cover these drugs, but rules vary. You will likely need prior authorization, which means your neurologist must submit medical records proving early-stage Alzheimer’s and amyloid confirmation. Some plans require step therapy, meaning you must try a lower-cost drug first. Others limit treatment to clinical trials or certified infusion centers. Always call your insurance company and ask for the exact coverage policy for lecanemab and donanemab before starting.
Manufacturer Support Programs
Both drug makers offer financial assistance. Eli Lilly runs the Leqembi Support Program, and Pfizer runs the Kisunla Support Program. These programs help cover copays, deductibles, and coinsurance for eligible patients. You do not need to qualify based on income to use them, but you must have commercial insurance or Medicare. Your clinic’s financial counselor can help you enroll during the prior authorization process.
How to Get Started on Treatment
Starting a new Alzheimer’s treatment requires coordination between your primary care doctor, a neurologist, and your insurance team. Follow these steps to move forward safely and efficiently.
- Step 1: Get a Specialist Evaluation. See a neurologist or memory clinic doctor. They will review your medical history, run cognitive tests, and order an amyloid PET scan or cerebrospinal fluid test.
- Step 2: Check Insurance Eligibility. Ask your insurer about coverage for amyloid-modifying drugs, prior authorization requirements, and in-network infusion centers.
- Step 3: Complete the Prior Authorization. Your doctor’s office will submit clinical notes, scan results, and the manufacturer’s coverage form to your insurance plan.
- Step 4: Schedule Your First Infusion. Once approved, your clinic will book your initial visit. Bring a list of all current medications, as some drugs interact with blood thinners or anti-inflammatories.
- Step 5: Follow the Monitoring Schedule. Keep all MRI appointments. Report any new headaches, vision changes, confusion, or balance issues to your doctor immediately.
“Early detection and timely treatment are the most important factors in slowing Alzheimer’s progression. Patients who start therapy during the mild cognitive impairment stage see the clearest benefits over time.” — National Institute on Aging, Alzheimer’s Disease Facts and Figures
Conclusion
The arrival of lecanemab and donanemab marks a major shift in Alzheimer’s care. These drugs do not reverse memory loss, but they can slow decline when started early. The financial and logistical steps are complex, but coverage has expanded, and manufacturer support programs make treatment more accessible than ever. Work closely with a neurologist, verify your insurance benefits early, and stay on schedule with MRI monitoring. If you are navigating a new diagnosis, take it one step at a time. The right treatment plan, combined with consistent care, can help you or your loved one maintain independence and quality of life for longer.